Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

About this update from Orion Oyj Class A

[{"type":"image","alt":"Orion Oyj","displaySize":"","headline":null,"caption":"Orion Oyj","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqzIu4PIU0vnnZUA5EUYng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0","width":300,"height":118}},"lazy":false},{"type":"text","content":"ORION CORPORATION INVESTOR NEWS 22 MAY 2025 at 10.15 EEST","length":60,"tagName":"p"},{"type":"text","content":"Orion to host Capital Markets Day today, 22 May 2025, in Helsinki","length":65,"tagName":"p"},{"type":"text","content":"Orion hosts its Capital Markets Day for analysts, institutional investors, bankers, and media representatives in Helsinki today, 22 May 2025. At the event, members of the Orion Executive Management Board will discuss Orion’s growth strategy, financial objectives, and businesses. Orion will not publish new strategic or financial targets in connection with the event.","length":367,"tagName":"p"},{"type":"text","content":"The presentation material is now published on Orion’s website https://www.orionpharma.com/cmd2025. The presentations include, among other things, the following information, which is of interest to investors, but is not considered to be material information about the company.","length":275,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the next 12 to 24 months, Orion aims to start clinical phase I trials with ODM-214, ODM-215 and ODM-216 which all are biologics (large molecule) and originate from Orion’s internal research.","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Easyhaler® product portfolio has potential to exceed EUR 300 million in peak annual sales.","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":283,"olType":false},{"type":"text","content":"Orion has three biologics assets for immuno-oncology indications in late research (candidate drug) phase. The company aims to start clinical phase I trials with these assets in the next 12 to 24 months. Of the assets ODM-2014 and ODM-216 are bi-specific antibodies and ODM-215 is a CAR-T cell therapy.","length":301,"tagName":"p"},{"type":"text","content":"The growth of ...

More updates from Orion Oyj Class A